Binding of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and related peptides to mu 1 and mu 2 opiate receptors.

Two endogenous brain peptides (Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2)), a cyclized analog and two fragments of Tyr-W-MIF-1, and hemorphin (Tyr-Pro-Trp-Thr) were tested for binding to mu 1 and mu 2 opiate receptor. All these peptides bound to both mu 1 and mu 2 sites in assays optimized to discriminate these subtypes of the mu opiate receptor in membranes from bovine thalamus. The cyclized analog of Tyr-W-MIF-1, previously shown to have potency near that of Tyr-D-Ala-Gly-N-MePhe-Gly-ol (DAMGO) and morphine in producing analgesia after intracerebroventricular (i.c.v.) injection, bound to mu 1 and mu 2 sites with affinities similar to those of DAMGO. Tyr-W-MIF-1, previously shown to induce analgesia after i.c.v. injection but with much higher potency after intrathecal (i.t.) injection, also bound to both mu 1 and mu 2 sites with an affinity between that of morphiceptin and hemorphin. Although the highest ratios of Ki's for mu 2/mu 1 were shown by hemorphin, Tyr-W-MIF-1, and Tyr-W-MIF-1, none of the compounds were significantly different in selectivity. The results indicate that the relatively lower potency of Tyr-W-MIF-1 after i.c.v., compared with i.t. injection, is not due to a lack of binding to mu 1 sites. They suggest that it has relatively high efficacy at mu 2, but low efficacy at mu 1 sites, a possibility that might explain some of the novel properties of these peptides.

Dopamine receptor antagonists block the effect of Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) on the opiate form of footshock-induced analgesia.

Previous studies have shown that some of CNS actions of an endogenous peptide Tyr-MIF-1, are mediated by dopamine (DA) receptors. To study the effect of DA receptor blockade on the antiopiate properties of Tyr-MIF-1, the opiate form of footshock-induced analgesia was elicited in the rat. The nociceptive responses were determined using the hot-plate test (52.5 degrees C). Intraperitoneal pre-treatment with haloperidol (500 micrograms/kg), SCH 23390 (150 micrograms/kg), or spiroperidol (150 micrograms/kg) potentiated the antinociceptive effect of the footshock and blocked the antagonistic action of Tyr-MIF-1 (200 micrograms/kg and 2.0 mg/kg). A dose of haloperidol too small to potentiate the antinociceptive effect of the footshock (100 micrograms/kg) was still able to block the action of Tyr-MIF-1 (200 micrograms/kg). The results suggest that activation of DA receptors mediates the antagonizing effect of Tyr-MIF-1 on the opiate form of footshock-induced analgesia in the rat.

The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.

In order to study the nigrostriatal pathway, we obtained the rotatory behavior model in male Wistar rats by electrolytic lesion of the left lateral hypothalamic region. Animals thus lesioned displayed rotations toward the same side of lesion when apomorphine was administered, a result in disagreement with what has been obtained in the model with 6-hydroxydopamine lesion. The administration of PLG alone was not followed by rotatory behavior but when the compound was administered in low doses (0.25 to 1mg/kg) simultaneously with apomorphine to animals previously submitted to REM sleep deprivation, a significant increase in the number of rotations was observed in comparison with controls and groups receiving higher doses of PLG. These results indicate that PLG may act as a modulator on dopamine receptors in the striatum.

The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.

An animal model of tardive dyskinesia was used for the evaluation of potential antidyskinetic properties of the neuropeptide L-Prolyl-L-Leucyl-glycinamide (PLG) and related drugs: cyclo[glycine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Gly) and cyclo[alanine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Ala). Dopaminergic supersensitivity was induced by repeated administration of the neuroleptic drug isofloxythepin. Isofloxythepin (5 mg/kg/day po) after the withdrawal increased Bmax of 3H-spiperone striatal binding sites, significantly decreased HVA level in the striatum and induced tolerance to the cataleptic effects challenged by perphenazine. PLG, c(CPC-Gly) and c(CPC-Ala) counteracted supersensitive responses of isofloxythepin. The use of c(CPC-Gly) and c(CPC-Ala) in the prevention of tardive dyskinesia is proposed.

Effect of prolyl-leucyl-glycinamide on blood pressure, heart rate and angiotensin converting enzyme activity in spontaneously hypertensive and Wistar-Kyoto normotensive rats.

The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated. A single s.c. injection of MIF at a lower dose (1 mg/kg) had no effect on the blood pressure of either SH or WKY rats when measured 1,4 and 7 hr after the injection of MIF. Higher doses of MIF (2 or 4 mg/kg), on the other hand, significantly depressed blood pressure in SH animals at 4 and 7 hr after the drug injection. However, MIF had no effect on the blood pressure of WKY rats. None of the doses of MIF had any appreciable effect on the heart rate of either SH or WKY rats. Angiotensin-converting enzyme (ACE) activity of anterior pituitary of WKY rats was significantly higher than that of SH rats. ACE activity of neurohypophysis, however, was lower in WKY rats than in SH rats. No change in the ACE activities of central and peripheral tissues (plasma, pituitary, striatum and hypothalamus) of SH rats was observed 4 hr after the administration of MIF (1, 2 or 4 mg/kg), a time at which MIF produced significant antihypertensive effect. It is concluded that MIF causes a delayed lowering of blood pressure only in the genetically hypertensive rats and that this effect is not mediated via an action on the ACE.

The effect of melanotropin release inhibiting factor, its metabolites and analogs on [3H]spiroperidol and [3H]apomorphine binding sites.

The effects of melanotrophin release inhibiting factor (Pro-Leu-Gly-NH2, MIF), its possible metabolites, Pro-Leu-OH, Leu-Gly-NH2, Leu-Gly-OH and an analogue, cyclo(Leu-Gly), on [3H]spiroperidol binding sites in the striatum and on [3H]apomorphine binding sites in the striatum and hypothalamus of male Sprague-Dawley rats were determined. [3H]Spiroperidol binding to dopamine receptors in striatal membranes was unaffected by any of the above peptides in concentration up to 0.1 mM. The binding of [3H]apomorphine was enhanced by MIF, Pro-Leu-OH and cyclo(Leu-Gly) in both striatal and hypothalamic membranes in submicromolar concentrations. Leu-Gly-NH2 and Leu-Gly-OH did not affect [3H]apomorphine binding to dopamine receptors in striatum of hypothalamus. The enhancement in binding of [3H]apomorphine by MIF and cyclo(Leu-Gly) was not related to the changes in the number of binding sites but to an increase in the affinity to the receptors. The results indicate that MIF and some of its related peptides do not affect dopamine receptor binding sites labeled by the neuroleptic [3H]spiroperidol but facilitate the transmission in those sites labeled by [3H]apomorphine. Since [3H]apomorphine and [3H]spiroperidol predominantly label pre- and post-synaptic dopamine receptors, it is concluded that MIF and its active analogs interact with presynaptic dopamine receptors.

Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices.

Release of alpha-MSH from male rat hypothalamic slices was studied using a sensitive bioassay (1-2 pg). Addition of 60 mM KCl to superfusion medium resulted in a twofold increase in alpha-MSH release compared to spontaneous release. Both spontaneous and potassium-induced release were inhibited in a dose-response manner by the tripeptide Pro-Leu-Gly-NH2 (PLG, or MIF-1); 0.04 microgram to 1 microgram PLG inhibited the alpha-MSH release but the lowest dose demonstrated a greater inhibitory effect; high concentrations of PLG, on the other hand, did not modify either spontaneous or potassium-evoked alpha-MSH release from the slices. Contrarily, DA did not modify either spontaneous or potassium- induced alpha-MSH release at any of the doses tested. These findings demonstrate that the inhibitory behavior of PLG and DA in the central nervous system (CNS) differs from their behavior towards alpha-MSH release in the pituitary. This suggests differences in the regulation of alpha-MSH release from the pituitary and the CNS.

Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.

It is well known that the release of melanocyte-stimulating hormone (MSH) from the pituitary gland is mainly controlled by an inhibitory influence from the hypothalamus. In addition to this inhibitory control, there may also be a stimulatory influence. Most, but by no means all, of the evidence is compatible with the possibility that inhibition is mediated by dopaminergic and/or alpha-adrenergic receptors. Gamma-aminobutyric acid also has been shown to have an inhibitory role in some studies. beta-Adrenergic receptors, serotonin, and acetylcholine may be involved in the stimulation of MSH release. Interaction of hypothalamic peptides like Pro-Leu-Gly-NH2(MIF-I) with biogenic amines, however, has not been excluded as a factor in the control of the release of MSH from the pituitary. Just as the evidence for the involvement of amines in the control of MSH release is somewhat puzzling and contradictory, conflicting evidence concerning their involvement in mediating the specific effects of MSH and MIF-I on the CNS remains unresolved.

The action of psychotropic drugs on DOPA induced behavioural responses in mice.

The "DOPA potentiation" test in mice was investigated for its usefulness in the detection of compounds with antidepressant properties. It was found that the anti-depressant drugs imipramine, amitriptyline, 5-methylamino-acetyl-6-methyl-5,6-dihydro-phenanthridine-HCl (Org OI77) and 1,2,3,4,10,14b-hexahydro-2-methyl-dibenzo[c,f]pyrazino[1,2-a]azepine-HCl (mianserin, Org GB 94) potentiated the behavioural effect of DOPA in groups of mice which had been treated 17 h previously with the monoamine oxidase inhibitor (MAOI) iproniazid. However, the DOPA response was also potentiated by a variety of centrally acting drugs which do not have antidepressant properties (atropine, methysergide, chlordiazepoxide, apomorphine). The peptide hormones ACTH4-10 and desglycinamide lysine vasopressin had equivocal effects while melanocyte stimulating hormone release-inhibiting factor (MIF) had no effect on the DOPA response. The DOPA response was inhibited by the neuroleptics chlorpromazine and haloperidol. There appeared to be no correlation between the effects of the drugs on the behavioural responses elicited by DOPA and the changes found in the brain concentration of noradrenaline, dopamine, serotonin, gamma-aminobutyric acid, tryptophan and tyrosine. It is concluded that the "DOPA potentiation" test cannot be considered as a reliable test in the detection of anti-depressant compounds.

Alpha-MSH and MIF-2 effects on serotonin levels and accumulation in various rat brain areas.

Levels as well as accumulation of serotonin (5-HT) were measured in various brain regions of the rat after administration of alpha-melanocyte-stimulating hormone (MSH) and Pro-Leu-Gly-NH2 (MIF-I). The method used in determining the serotonin measured both 5-OH-tryptamine (5-HT) and 5-methoxytryptamine (5-MT). No statistically significant changes in levels or accumulation of serotonin after pargyline injection were found when unoperated control rats were treated with either MSH or MIF-I. Similar treatment of hypophysectomized rats indicated that both peptides significantly (p less than 0.05) lowered serotonin accumulation only in the area of the frontal cortex; a similar but smaller, not statistically significant, decrease was seen in the hypothalamus and hippocampus of the hypophysectomized rat. Since only hypophysectomized rats were affected, no correlation between the behavioral effects of these peptides (which has been found to occur in both unoperated and hypophysectomized rats) and the biochemical changes could be made.